Therapy of chronic hepatitis B: trends and developments

Current Opinion in Pharmacology

Volumn 8, Issue 5, 2008, Pages 532-540

  Delaney IV, William E ^a   Borroto Esoda, Katyna ^b  

^a GILEAD SCIENCES   (United States)

^b GILEAD SCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; EMTRICITABINE; ENTECAVIR; IMMUNOMODULATING AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PLACEBO; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MONOTHERAPY; NONHUMAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; VIRUS INHIBITION; VIRUS MUTATION;

ANIMALS; ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES;

EID: 54849417161     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.09.008     Document Type: Review

References (58)

1. EASL Jury. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 38 (2003) 533-540
2. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61 (1988) 1942-1956
3. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., Huang G.T., and Iloeje U.H. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
4. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., and Chen C.J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
5. Marcellin P., Hadziyannis S., Mondou E., Arterburn S., Borroto-Esoda K., Miller M.D., Frederick D., and Rousseau F. Week 48 HBV DNA and 5 years risk of resistance to adefovir dipivoxil (ADV) in patients with HBeAg-negative chronic hepatitis B (CHB) [poster LB-7]. 20th International Conference on Antirviral Research (ICAR) April 29-May 3 (2007), Palm Springs, California, USA
6. DiBisceglie A., Lai C.-L., Gane E., Chen Y.-C., Thongsawat S., Wang Y., Chen Y., Heathcote E.J., Zeuzem S., Rasenack J., et al. Telbivudine Globe Trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients [abstract]. Hepatology 44 (2006) 230A-231A 112 Abstract
7. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., and Lok A.S. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45 (2007) 1056-1075
8. Lai C.L., and Yuen M.F. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Int Med 147 (2007) 5
9. Keeffe E.B., Dieterich D.T., Han S.H., Jacobson I.M., Martin P., Schiff E.R., Tobias H., and Wright T.L. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 (2006) 936-962. Provides recent guidelines the selection of patients for CHB treatment and a description of therapies available at the time of publication (ETV, ADV, LAM and pegylated-interferon-α).
10. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539. The most recent AASLD treatment guidelines for CHB which summarize preferred treatment options for various CHB patient populations. Includes a clinical summary and recommendations for use of LAM, ADV, ETV, L-dT as well as interferon-based therapies.
11. Dienstag J.L., Schiff E.R., Wright T.L., Perrillo R.P., Hann H.-W., Goodman Z., Crowther L., Condreay L.D., Woessner M., Rubin M., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 (1999) 1256-1263
12. Tassopoulos N.C., Volpes R., Pastore G., Heathcote J., Buti M., Goldin R.D., Hawley S., Barber J., Condreay L., Gray D.F., et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29 (1999) 889-896
13. Chang T.-T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.-C., Lok A.S., Han K.-H., Goodman Z., Zhu J., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1110
14. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., Chen Y., Heathcote E.J., Rasenack J., Bzowej N., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588. Summarizes the results of the GLOBE study, the phase 3 registrational studies telbivudine in both HBeAg+ patients and HBeAg- patients. Telbivudine is studied using a head-to-head trial design with lamivudine which allows direct comparison of safety, efficacy and resistance.
15. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., DeHertogh D., Wilber R., Zink R.C., Cross A., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1020
16. Guan R., Lai C.L., Liaw Y.F., Lim S.G., and Lee C.M. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 16 (2001) A60 Abstract 187
17. Marcellin P., Chang T.-T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., Jeffers L., Goodman Z., Wulfsohn M.S., Xiong S., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
18. Hadziyannis S.J., Tassopoulos N., Heathcote E.J., Chang T.-T., Kitis G., Rizzetto M., Marcellin P., Lim S.G., Goodman Z., Wulfsohn M.S., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
19. Heathcote E.J., Gane E., DeMan R., Lee S., Flisiak R., Manns M.P., Tchernev K., Kurdos O., Shiffman M., Sorbel J., et al. A randomized, double-blind comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBEAG-positive chronic hepatitis B (CHB): study GS-US-174-0103 [AASLD Abstracts]. Hepatology 46 (2007) 861A. This abstract and presentation at the 2007 AASLD meeting summarizes the 48 week safety, efficacy and resistance results of the phase 3 registrational studies for TDF. The study design provides a head-to-head comparison of TDF to ADV which demonstrates the superior efficacy of TDF.
20. Leung N., Peng C., Sollano J., Lesmana L., Yuen M.-F., Jeffers L., Hann H., Sherman M., Zhu J., Mencarini K., et al. Entecavir (ETV) results in higher HBV-DNA reduction vs adefovir (ADV) in chronically infected HBeAg+ antiviral-naïve adults: 48 week results (E.A.R.L.Y. Study) [oral presentation 49]. 42nd Annual Meeting of the European Association for the Study of the Liver April 11-15. Barcelona, Spain (2007)
21. Marcellin P., Buti M., Krastev Z., Germanidis G., Kaita K., Kotzev I., Buggisch P., Weilert F., Trinh H., Sorbel J., et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102 [oral presentation]. 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) November 2-6. Boston, Mass, USA (2007)
22. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., Marcellin P., Lim S.G., Goodman Z., Ma J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 Years. Gastroenterology 131 (2006) 1743-1751. Summarizes the long-term safety, efficacy and resistance data for ADV in HBeAg- CHB by following patients completing a 96 week double blind phase 3 study on open-label therapy for an additional three years.
23. Schiff E., Lai C.-L., Hadziyannis S., Neuhaus P., Terrault N., Colombo M., Tillmann H., Samuel D., Zeuzem S., Vileneuve J.-P., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 13 (2007) 349-360
24. Westland C.E., Yang H., Delaney IV W.E., Wulfsohn M., Lama N., Gibbs C.S., Miller M.D., Fry J., Brosgart C.L., Schiff E.R., et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepatitis 12 (2005) 67-73
25. Benhamou Y., Thibault V., Vig P., Calvez V., Marcelin A.-G., Fievet M.-H., Currie G., Chang C.G., Biao L., Xiong S., et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 44 (2006) 62-67
26. Lampertico P., Vigano M., Manenti E., Iavarone M., Sablon E., and Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133 (2007) 1445-1451. Data from this large cohort of LAM-resistant patients shows that treatment intensification by adding ADV therapy to ongoing LAM therapy results in prolonged suppression of HBV DNA with very low risk of developing ADV-resistance mutations over three years.
27. Chang T.T., Gish R.G., Hadziyannis S.J., Cianciara J., Rizzetto M., Schiff E.R., Pastore G., Bacon B.R., Poynard T., Joshi S., et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129 (2005) 1198-1209
28. Yang H., Qi X., Sabogal A., Miller M., Xiong S., and Delaney IV W.E. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antiv Ther 10 (2005) 625-633
29. Sherman M., Yurdaydin C., Sollano J., Silva M., Liaw Y.F., Cianciara J., Boron-Kaczmarska A., Martin P., Goodman Z., Colonno R., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130 (2006) 2039-2049
30. Sherman M., Yurdaydin C., Simsek H., Silva M., Liaw Y.F., Rustgi V.K., Sette H., Tsai N., Tenney D.J., Vaughan J., et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 48 (2008) 99-108
31. Gish R.G., Lok A.S., Chang T.T., de Man R.A., Gadano A., Sollano J., Han K.H., Chao Y.C., Lee S.D., Harris M., et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133 (2007) 1437-1444. Summarizes the results of the phase 3 registrational studies for ETV in HBeAg+ patients through 96 weeks. ETV is studied using a head-to-head trial design with lamivudine which allows direct comparison of safety and efficacy. Also describes how patients either continued or discontinued ETV therapy at the end of 52 weeks based on classification as responders, non-responders, and virologic responders.
32. Tenney D.J., Pokornowski K.A., Rose R.E., Baldick C.J., Eggers B.J., Fang J., Yang J.Y., Xu D., Brett-Smith L., Kreter B., et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance [abstract]. Hepatol Int 2 (2008) S76-77 Abstract OL-107. Abstract and presentation at 2008 APASL meeting summarizes the results of long-term ETV resistance surveillance in treatment-naive and lamivudine resistant patient populations.
33. Sasadeusz J., Audsley J., Mijch A., Baden R., Caro J., Hunter H., Matthews G., McMahon M.A., Olender S.A., Siliciano R.F., et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 22 (2008) 947-955
34. Domaoal R.A., McMahon M., Thio C.L., Bailey C.M., Tirado-Rives J., Obikhod A., Detorio M., Rapp K.L., Siliciano R.F., Schinazi R.F., et al. Pre-steady-state kinetic studies establish entecavir 5′-triphosphate as a substrate for HIV-1 reverse transcriptase. J Biol Chem 283 (2008) 5452-5459
35. Heathcote J., George J., Gordon S., Bronowicki J.-P., Sperl J., Williams R.R., Martin P., Beniowski M., Sorbel J., Anderson J., et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovirdipivoxilswitch data (study 103) [oral presentation #1593]. 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) April 23-27. Milan, Italy (2008)
36. Marcellin P., Jacobson I., Habersetzer F., Senturk H., Andreone P., Moyes C., Horban A., Teuber G., Sorbel J., Anderson J., et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102) [oral presentation #1602]. 43rd Annual Meeting of the European Association for the Study of the Liver (EASL). Milan, Italy (2008)
37. Qi X., Xiong S., Yang H., Miller M., and Delaney IV W.E. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antiv Ther 12 (2007) 355-362
38. van Bömmel F., and Berg T. Role of tenofovir in the treatment of chronic HBV infection. Future Virol 3 (2008) 207-220. A comprehensive review of existing preclinical and clinical data regarding the use of TDF to treat CHB. Summarizes and comments on the results of many investigator sponsored studies of TDF use in lamivudine-resistant and HIV co-infected populations.
39. Lai C.-L., Chien R.-N., Leung N.W.Y., Chang T.-T., Guan R., Tai D.-I., Ng K.-Y., Wu P.-C., Dent J.C., Barber J., et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339 (1998) 61-68
40. Lai C.-L., Gane E., Hsu C.-W., Thongsawat S., Wang Y., Chen Y., Heathcote E.J., Rasenack J., Bzowej N., Naoumov N., et al. Two-year results from the globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine [abstract]. Hepatology 4 (2006) 222A Abstract 291
41. Fung S.K., Mazzulli T., Sherman M., Popovic V., Ramos M., and Sablon E. Pre-existing antiviral resistance mutations among treatment-naive HBV patients can be detected by a sensitive line probe assay [poster]. J Hepatol 2 (2008) S256 Poster 688
42. Zoulim F., Buti M., and Lok A.S. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?. J Viral Hepat 14 Suppl. 1 (2007) 29-36. This review provides an insightful overview of molecular and clinical aspects of drug resistance and includes thoughts on which therapies can be used to rescue first line treatment-failure and prospects for avoiding and managing drug resistance in the future.
43. Villeneuve J.-P., Durantel D., Durantel S., Westland C., Xiong S., Brosgart C.L., Gibbs C.S., Parvaz P., Werle B., Trepo C., et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 39 (2003) 1085-1089
44. Fung S.K., Chae H.B., Fontana R.J., Conjeevaram H., Marrero J., Oberhelman K., Hussain M., and Lok A.S. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44 (2006) 283-290
45. Reijnders J., De Man R.A., Pas S.D., Schutten M., and Janssen H.L. Entecavir: a rescue therapy for chronic hepatitis B patients with a limited virological response to adefovir? [abstract]. Hepatology 46 (2007) 660A Abstract 951
46. Berg T., Moller B., Trinh H., Chan S., Marcellin P., Suarez E., Snow-Lampart A., Frederick D., Oldach D., Sorbel J., et al. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for Treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV) [Abstract #76]. J Hepatol 48 (2008) S34
47. van Bommel F., de Man R.A., Erhardt A., Huppe D., Stein K., Buggisch P., Bocher W., Sarrazin C., Wedemeyer H., Trojan J., et al. First multicenter evaluation of the efficacy of Tenofovir in nucleos(t)ide analog experienced patients with HBV monoinfection [oral presentation]. 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) November 2-6. Boston, MA (2007)
48. Tan J., Degertekin B., Wong S.N., Husain M., Oberhelman K., and Lok A.S. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 48 (2008) 391-398
49. Jardi R., Rodriguez-Frias F., Schaper M., Ruiz G., Elefsiniotis I., Esteban R., and Buti M. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J Viral Hepat 14 (2007) 835-840
50. Villet S., Ollivet A., Pichoud C., Barraud L., Villeneuve J.P., Trepo C., and Zoulim F. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 46 (2007) 531-538
51. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., Discotto L., Plym M., Pokornowski K., Yu C.F., Angus P., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 48 (2004) 3498-3507
52. Leemans W.F., Niesters H.G., van der Eijk A.A., Janssen H.L., Schalm S.W., and de Man R.A. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. Eur J Gastroenterol Hepatol 20 (2008) 773-777
53. Sung J.J., Lai J.Y., Zeuzem S., Chow W.C., Heathcote E.J., Perrillo R.P., Brosgart C.L., Woessner M.A., Scott S.A., Gray D.F., et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 48 (2008) 728-735
54. Hui C.K., Zhang H.Y., Bowden S., Locarnini S., Luk J.M., Leung K.W., Yueng Y.H., Wong A., Rousseau F., Yuen K.Y., et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 48 (2008) 714-720
55. Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., Han S., Poynard T., Myers M., Chao G., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
56. Mutimer D., Pillay D., Cook P., Ratcliffe D., O'Donnell K., Dowling D., Shaw J., Elias E., and Cane P.A. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis 181 (2000) 713-716
57. Rapti I., Dimou E., Mitsoula P., and Hadziyannis S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45 (2007) 307-313
58. Leung N., Peng C., Sollano J., Lesmana L., Yuen M., Jeffers L., Hann H., Sherman M., Zhu J., and Mencarini K. Entecavir (ETV) results in higher HBV-DNA reduction vs adefovir (ADV) in chronically infected HBeAg(+) antiviral-naive adults: 48 week results (E.A.R.L.Y. Study) [Abstract 49]. J Hepatol 46 (2007) S24